Metsera: Accepts Pfizer's $10 billion acquisition offer.

American biopharmaceutical company Metsera announced on November 7 that it has reached a revised merger agreement with Pfizer. According to the agreement, Pfizer will acquire Metsera at a price of up to $86.25 per share, including $65.60 per share in cash and a contingent value right that could allow shareholders to receive an additional cash payment of up to $20.65 per share. The announcement stated that Metsera has accepted Pfizer's $10 billion acquisition offer.